TriangleNCT01962103 · CITED IN SOURCE DOCUMENTS
Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE1, PHASE2
- Status at capture
- COMPLETED
- Registry last update
- 2019-12-27
The purpose of this study is to find the safe dose of nab-paclitaxel in children with solid tumors, and to see if it works to treat these solid tumors in children and young adults (in Phase 1 ≤ 18 years old and in Phase 2 ≤ 24 years old). After the final dose has been chosen, patients will be enrolled according to the specific solid tumor type, (neuroblastoma, rhabdomyosarcoma, or Ewing's sarcoma), to see how nab-paclitaxel works in treating these tumors.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs)
Phase 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Phase 2: Overall Response Rate (ORR)
Phase 1: ORR
Phase 1: Maximum Observed Concentration of Paclitaxel in Blood Plasma (Cmax)
Phase 1: Cmax - Dose-Normalized
Phase 1: Area Under the Plasma Concentration-Time Curve (AUC)
Phase 1: AUC - Dose-Normalized
Phase 1: Clearance (CL)
Phase 1: CL - Body Surface Area (BSA)-Normalized
Phase 1: Volume of Distribution (Vss)
Phase 1: Vss - BSA-Normalized
Phase 1 and 2 Population PK: Volume of Distribution of the Central Compartment (V1)
Phase 1 and 2 Population PK: Maximum Elimination Rate From the Central Compartment (VMEL)
Phase 1 and 2 Population PK: Concentration in the Central Compartment at 50% of VMEL (KMEL)
Phase 1 and 2 Population PK: Intercompartmental CL Between the Central Compartment and the First Peripheral Compartment (Q2)
Phase 1 and 2 Population PK: Intercompartmental CL Between the Central Compartment and the Second Peripheral Compartment (Q3)
Phase 1 and 2 Population PK: Volume of Distribution of the First Peripheral Compartment (V2)
Phase 1 and 2 Population PK: Volume of Distribution of the Second Peripheral Compartment (V3)
Phase 2: Duration of Response (DOR)
Phase 2: Disease Control Rate (DCR)
Phase 2: Progression-Free Survival (PFS)
Phase 2: Kaplan-Meier Estimate of Overall Survival Rate at 1 Year
Phase 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Patients must meet all of the following criteria to be enrolled in the study: 1. Patient has a confirmed solid tumor diagnosis according to the following: 1. Phase 1: patient has a recurrent or refractory solid tumor that has progressed or did not respond to standard therapy, or for which no standard anticancer therapy exists 2. Phase 2: patient has radiologically documented measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (for neuroblastoma, evaluable disease by 123\^I-metaiodobenzylguanidine \[MIBG\]/Curie score is also acceptable) in 1 of the following tumor types and has failed up to 3 lines of treatment: Group 1: neuroblastoma, Group 2: rhabdomyosarcoma; Group 3: Ewing's sarcoma. 2. The patient has a Lansky/Karnofsky performance status score of ≥ 70%. 3. The patient has adequate serum chemistry levels, evidenced by the following laboratory values 1. aspartate aminotransferase (AST)/serum glutamic-oxaloacetric transaminase (SGOT), alanine aminotransferase (ALT)/serum glutamic pyruvate transaminase (SGPT) ≤ 2.5 × upper limit of normal range (ULN) 2. Total bilirubin ≤ 1.5 × ULN 3. Creatinine ≤ 1.5 × ULN 4. The patient has adequate bone marrow function, evidenced by the following: 1. Absolute neutrophil count ≥ 1.0 × 10\^9 cells/L 2. Platelets ≥ 80 × 10\^9 cells/L (transfusion independent, defined as not receiving platelet transfusions within 7 days prior to laboratory sample). In the phase 2 portion, for patients with known bone marrow involvement, platelets ≥ 50 × 10\^9 cells/L 3. Hemoglobin ≥ 8 g/dL (transfusion is permitted to fulfill this criterion). 5. The patient (when applicable) or patient's parent(s) or legal guardian(s) understand(s) and voluntarily signed an informed consent document prior to any study-related assessments/procedures being conducted. Where locally applicable, the patient also understands and voluntarily provides his/her assent prior to any study-related assessments/procedures being conducted. 6. Male patients of childbearing potential must use a condom during sexual intercourse and shall not father a child during the study and for 6 months after the last dose of study medication. 7. Female patients of childbearing potential \[defined as all female patients ≥ 12 years old or who have reached menarche, whichever occurs first\] must have both of the following: a. Agree to the use of two physician-approved contraceptive methods simultaneously or practice complete abstinence while on study medication or for a longer period if required by regulations. i. True abstinence: When this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception. ii. Acceptable contraceptive methods include: oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) including at least one barrier method. b. Have negative serum pregnancy test result at screening confirmed by negative urine pregnancy dipstick within 72 hours prior to first dose of investigational product (if serum test occurred \> 72 hours from first dose); pregnancy test with sensitivity of at least 25 mIU/mL. Exclusion Criteria: * The presence of any of the following will exclude a patient from enrollment: <!-- --> 1. The patient has a primary brain tumor(s) or brain metastasis (unless metastasis is treated and stable for \> 28 days). In patients who are symptomatic, a brain scan is required to exclude metastasis. 2. The patient has received therapeutic dose chemotherapy or radiotherapy ≤ 21 days prior to start of investigational product. 3. The patient has received maintenance dose chemotherapy (e.g., low dose cyclophosphamide) ≤ 7 days from the first dose of investigational product. 4. The patient has received any investigational therapy ≤ 28 days prior to start of investigational product. Investigational therapy is defined as any medicinal product that is not approved in the country of treatment for any indication, adult or pediatric. 5. The patient has received any biological therapy ≤ 7 days prior to the start of investigational product, or monoclonal antibody ≤ 3 half-lives or 28 days, whichever is shorter, prior to the first dose of investigational product. 6. The patient has received any hematopoietic stem cell transplantation (HSCT) ≤ 3 months prior to start of investigational product. 7. The patient has received allogeneic hematopoietic stem cell transplantation (HSCT) ≤ 3 months or autologous HSCT ≤ 21 days prior to start of investigational product. 8. The patient has not recovered from the acute toxic effects of prior chemotherapy, radiation, or major surgery/significant trauma. 9. The patient has had minor surgery ≤ 7 days from the start of study treatment (excluding the placement of central/peripheral lines, skin biopsy). 10. The patient has a known history of stroke, myocardial infarction, peripheral vascular disease, or recent (within 3 months) uncontrolled deep venous thrombosis. 11. The patient has a known history or current diagnosis of human immunodeficiency virus (HIV) infection, regardless of treatment status. 12. The patient has an uncontrolled intercurrent illness including but not limited to ongoing or active infection requiring antibiotic, antifungal, or antiviral therapy, symptomatic heart failure, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. 13. The patient has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the patient from participating in the study. 14. The patient has any condition, including the presence of laboratory abnormalities, that places the patient at unacceptable risk if he/she were to participate in the study. 15. The patient has any condition that confounds the ability to interpret data from the study. 16. The patient or parent(s)/guardian(s) is/are unable to comply with the study visit schedule and other protocol requirements, in the opinion of the investigator. 17. The patient has ≥ Grade 2 peripheral neuropathy by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) at screening.
- healthy Volunteers
- false
- maximum Age
- 24 Years
- minimum Age
- 6 Months
- sex
- ALL
- std Ages
- CHILD
- ADULT
Treatment arms and interventions
- arm Groups
- description
- nab-paclitaxel 100-240 mg/m2 IV on Days 1, 8 and 15 of a 28-day cycle.
- intervention Names
- Drug: nab-paclitaxel
- label
- nab-paclitaxel
- type
- EXPERIMENTAL
- description
- nab-paclitaxel 120 mg/m\^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
- intervention Names
- Drug: nab-paclitaxel
- label
- Phase 1: Nab-Paclitaxel 120 mg/m^2
- type
- EXPERIMENTAL
- description
- nab-paclitaxel 150 mg/m\^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
- intervention Names
- Drug: nab-paclitaxel
- label
- Phase 1: Nab-Paclitaxel 150 mg/m^2
- type
- EXPERIMENTAL
- description
- nab-paclitaxel 180 mg/m\^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
- intervention Names
- Drug: nab-paclitaxel
- label
- Phase 1: Nab-Paclitaxel 180 mg/m^2
- type
- EXPERIMENTAL
- description
- nab-paclitaxel 210 mg/m\^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
- intervention Names
- Drug: nab-paclitaxel
- label
- Phase 1: Nab-Paclitaxel 210 mg/m^2
- type
- EXPERIMENTAL
- description
- nab-paclitaxel 240 mg/m\^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
- intervention Names
- Drug: nab-paclitaxel
- label
- Phase 1: Nab-Paclitaxel 240 mg/m^2
- type
- EXPERIMENTAL
- description
- nab-paclitaxel 270 mg/m\^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
- intervention Names
- Drug: nab-paclitaxel
- label
- Phase 1: Nab-Paclitaxel 270 mg/m^2
- type
- EXPERIMENTAL
- description
- Participants with Ewing's sarcoma: nab-paclitaxel at the RP2D (240 mg/m\^2 in participants weighing \> 10 kg and 11.5 mg/kg in participants weighing ≤ 10 kg) IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity.
- intervention Names
- Drug: nab-paclitaxel
- label
- Phase 2: Ewing's Sarcoma
- type
- EXPERIMENTAL
- description
- Participants with neuroblastoma: nab-paclitaxel at the RP2D (240 mg/m\^2 in participants weighing \> 10 kg and 11.5 mg/kg in participants weighing ≤ 10 kg) IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity.
- intervention Names
- Drug: nab-paclitaxel
- label
- Phase 2: Neuroblastoma
- type
- EXPERIMENTAL
- description
- Participants with rhabdomyosarcoma: nab-paclitaxel at the RP2D (240 mg/m\^2 in participants weighing \> 10 kg and 11.5 mg/kg in participants weighing ≤ 10 kg) IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity.
- intervention Names
- Drug: nab-paclitaxel
- label
- Phase 2: Rhabdomyosarcoma
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- nab-paclitaxel
- description
- nab-paclitaxel 120-270 mg/m2 IV on Days 1, 8 and 15 of a 28-day cycle
- name
- nab-paclitaxel
- other Names
- Abraxane
- type
- DRUG
- arm Group Labels
- Phase 1: Nab-Paclitaxel 120 mg/m^2
- Phase 1: Nab-Paclitaxel 150 mg/m^2
- Phase 1: Nab-Paclitaxel 180 mg/m^2
- Phase 1: Nab-Paclitaxel 210 mg/m^2
- Phase 1: Nab-Paclitaxel 240 mg/m^2
- Phase 1: Nab-Paclitaxel 270 mg/m^2
- Phase 2: Ewing's Sarcoma
- Phase 2: Neuroblastoma
- Phase 2: Rhabdomyosarcoma
- description
- IV infusion
- name
- nab-paclitaxel
- other Names
- Abraxane
- type
- DRUG
Study design
- allocation
- NON_RANDOMIZED
- intervention Model
- SINGLE_GROUP
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 107
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- A DLT was defined as investigational product (IP)-related adverse events occurring during the DLT assessment period that led to treatment discontinuation or met one of the following criteria: - Common Terminology Criteria for Adverse Events (CTCAE) Grade (Gr) 3 or 4 nonhematologic toxicity (excluding transient transaminitis) - CTCAE Gr 3 or 4 nausea or vomiting that persisted \> 5 days despite maximal anti-emetic treatment - CTCAE Gr 4 thrombocytopenia or anemia that persisted \> 7 days or required transfusion \> 7 days - CTCAE Gr 3 thrombocytopenia with bleeding - CTCAE Gr 4 uncomplicated neutropenia lasting \> 7 days - Febrile neutropenia with confirmed bacterial infection - CTCAE Gr 3 hematologic toxicity requiring treatment (tx) delay \> 21 days. Use of "..." in the table rows signifies the continuation of row title per the above list.
- measure
- Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs)
- time Frame
- DLT assessment period: For participants > 10 kg: the first 28-day cycle including Cycle 2 Day 1 predose evaluations; for participants ≤ 10 kg: the first two 28-day cycles including Cycle 3 Day 1 predose evaluations
- description
- An adverse event (AE) was defined as any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. A serious AE (SAE) is any AE occurring at any dose that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. TEAEs were defined as AEs that began or worsened in severity on or after the date of the first dose of study drug and within 28 days of the date of the last dose of study drug. The severity of an AE was graded according to the CTCAE, Version 4.0.
- measure
- Phase 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
- time Frame
- Median treatment duration in Phase 1 was 7.0 weeks, with minimum and maximum duration of 1 and 49 weeks, respectively. Participants were followed for 28 days after discontinuing treatment for safety and monitoring of AEs.
- description
- Overall response rate was defined as the percentage of participants who achieved a complete response (CR; disappearance of all target lesions) or partial response (PR; at least a 30% decrease in the sum of diameters of target lesions) confirmed no less than 4 weeks after the criteria for response were first met using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 guidelines. (For Phase 2 neuroblastoma participants who had both RECIST and Curie Score tumor evaluations, both tumor response results were considered and an overall response was derived.) Confidence interval was obtained using the Clopper-Pearson method.
- measure
- Phase 2: Overall Response Rate (ORR)
- time Frame
- Median treatment duration in Phase 2 per group: Ewings Sarcoma = 14 weeks (3-31), Neuroblastoma = 7 weeks (3-23), Rhabdomyosarcoma = 5 weeks (1-13).
- secondary Outcomes
- description
- Overall response rate was defined as the percentage of participants who achieved a complete response (CR; disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions) confirmed no less than 4 weeks after the criteria for response were first met) using RECIST version 1.1 guidelines over the total number of participants available for the analysis. Confidence interval was obtained using the Clopper-Pearson method.
- measure
- Phase 1: ORR
- time Frame
- Median treatment duration in Phase 1 was 7.0 weeks, with minimum and maximum duration of 1 and 49 weeks, respectively.
- measure
- Phase 1: Maximum Observed Concentration of Paclitaxel in Blood Plasma (Cmax)
- time Frame
- Cycle 1 Day 1 (Participants ≥ 6 years: 1-2 minutes prior to the end of infusion [EOI], and 15 minutes, 1, 3, 5, 8, 24, 48, and 72 hours after the EOI. Participants <6 years: 1-2 minutes prior to the EOI, and 15 minutes, 3, 5, and 24 hours after the EOI.)
- measure
- Phase 1: Cmax - Dose-Normalized
- time Frame
- Cycle 1 Day 1 (Participants ≥ 6 years: 1-2 minutes prior to the end of infusion [EOI], and 15 minutes, 1, 3, 5, 8, 24, 48, and 72 hours after the EOI. Participants <6 years: 1-2 minutes prior to the EOI, and 15 minutes, 3, 5, and 24 hours after the EOI.)
- description
- Measurements include: AUC from time zero to the last measurable concentration (AUCt), AUC from time zero to 24 hours (AUC24), and AUC from time zero to infinity (AUCinf).
- measure
- Phase 1: Area Under the Plasma Concentration-Time Curve (AUC)
- time Frame
- Cycle 1 Day 1 (Participants ≥ 6 years: 1-2 minutes prior to the end of infusion [EOI], and 15 minutes, 1, 3, 5, 8, 24, 48, and 72 hours after the EOI. Participants <6 years: 1-2 minutes prior to the EOI, and 15 minutes, 3, 5, and 24 hours after the EOI.)
- description
- Measurements include: AUC24 and AUCinf.
- measure
- Phase 1: AUC - Dose-Normalized
- time Frame
- Cycle 1 Day 1 (Participants ≥ 6 years: 1-2 minutes prior to the end of infusion [EOI], and 15 minutes, 1, 3, 5, 8, 24, 48, and 72 hours after the EOI. Participants <6 years: 1-2 minutes prior to the EOI, and 15 minutes, 3, 5, and 24 hours after the EOI.)
- description
- Measurement of renal clearance from the body.
- measure
- Phase 1: Clearance (CL)
- time Frame
- Cycle 1 Day 1 (Participants ≥ 6 years: 1-2 minutes prior to the end of infusion [EOI], and 15 minutes, 1, 3, 5, 8, 24, 48, and 72 hours after the EOI. Participants <6 years: 1-2 minutes prior to the EOI, and 15 minutes, 3, 5, and 24 hours after the EOI.)
- description
- Measurement of renal clearance from the body.
- measure
- Phase 1: CL - Body Surface Area (BSA)-Normalized
- time Frame
- Cycle 1 Day 1 (Participants ≥ 6 years: 1-2 minutes prior to the end of infusion [EOI], and 15 minutes, 1, 3, 5, 8, 24, 48, and 72 hours after the EOI. Participants <6 years: 1-2 minutes prior to the EOI, and 15 minutes, 3, 5, and 24 hours after the EOI.)
- measure
- Phase 1: Volume of Distribution (Vss)
- time Frame
- Cycle 1 Day 1 (Participants ≥ 6 years: 1-2 minutes prior to the end of infusion [EOI], and 15 minutes, 1, 3, 5, 8, 24, 48, and 72 hours after the EOI. Participants <6 years: 1-2 minutes prior to the EOI, and 15 minutes, 3, 5, and 24 hours after the EOI.)
- measure
- Phase 1: Vss - BSA-Normalized
- time Frame
- Cycle 1 Day 1 (Participants ≥ 6 years: 1-2 minutes prior to the end of infusion [EOI], and 15 minutes, 1, 3, 5, 8, 24, 48, and 72 hours after the EOI. Participants <6 years: 1-2 minutes prior to the EOI, and 15 minutes, 3, 5, and 24 hours after the EOI.)
- description
- Population PK analysis was performed using nonlinear mixed effect modeling. The estimated allometric function for V1 was 0.888.
- measure
- Phase 1 and 2 Population PK: Volume of Distribution of the Central Compartment (V1)
- time Frame
- Cycle 1 Day 1 (Participants ≥ 6 years: 1-2 minutes prior to the end of infusion [EOI], and 15 minutes, 1, 3, 5, 8, 24, 48, and 72 hours after the EOI. Participants < 6 years: 1-2 minutes prior to the EOI, and 15 minutes, 3, 5, and 24 hours after the EOI.)
- description
- Population PK analysis was performed using nonlinear mixed effect modeling. The estimated allometric function for VMEL was 1.12.
- measure
- Phase 1 and 2 Population PK: Maximum Elimination Rate From the Central Compartment (VMEL)
- time Frame
- Cycle 1 Day 1 (Participants ≥ 6 years: 1-2 minutes prior to the end of infusion [EOI], and 15 minutes, 1, 3, 5, 8, 24, 48, and 72 hours after the EOI. Participants < 6 years: 1-2 minutes prior to the EOI, and 15 minutes, 3, 5, and 24 hours after the EOI.)
- description
- Population PK analysis was performed using nonlinear mixed effect modeling.
- measure
- Phase 1 and 2 Population PK: Concentration in the Central Compartment at 50% of VMEL (KMEL)
- time Frame
- Cycle 1 Day 1 (Participants ≥ 6 years: 1-2 minutes prior to the end of infusion [EOI], and 15 minutes, 1, 3, 5, 8, 24, 48, and 72 hours after the EOI. Participants < 6 years: 1-2 minutes prior to the EOI, and 15 minutes, 3, 5, and 24 hours after the EOI.)
Full study description
- brief Summary
- The purpose of this study is to find the safe dose of nab-paclitaxel in children with solid tumors, and to see if it works to treat these solid tumors in children and young adults (in Phase 1 ≤ 18 years old and in Phase 2 ≤ 24 years old). After the final dose has been chosen, patients will be enrolled according to the specific solid tumor type, (neuroblastoma, rhabdomyosarcoma, or Ewing's sarcoma), to see how nab-paclitaxel works in treating these tumors.
- detailed Description
- ABI-007-PST-001 is a Phase 1/2, multicenter, open-label, dose-finding study to assess the safety , tolerability, and preliminary efficacy of weekly nab-paclitaxel in pediatric patients with recurrent or refractory solid tumors (excluding brain tumors). The Phase 1 portion of the study, with a dose escalation design, ended and the recommended Phase 2 dose (RP2D) was determined as 240 mg/m\^2 intravenously (IV) in patients weighing \> 10 kg and 11.5 mg/kg in patients weighing ≤ 10 kg, on Days 1, 8 and 15 of a 28-day cycle. The Phase 2 portion of the study will enroll additional patients at the RP2D into 1 of 3 solid tumor groups \[neuroblastomas, rhabdomyosarcomas, Ewing's sarcomas\]. Both phases of the study are open-label and conducted at multiple centers. The Phase 2 is using a Simon 2-stage design to monitor patient enrollment for each group separately. The rhabdomyosarcoma group, neuroblastoma or Ewing's sarcoma groups did not reach the expected number of 2 responders out of 14 efficacy eligible patients. Consequently, the groups were stopped.
Source references
- references
- citation
- Moreno L, Casanova M, Chisholm JC, Berlanga P, Chastagner PB, Baruchel S, Amoroso L, Gallego Melcon S, Gerber NU, Bisogno G, Fagioli F, Geoerger B, Glade Bender JL, Aerts I, Bergeron C, Hingorani P, Elias I, Simcock M, Ferrara S, Le Bruchec Y, Slepetis R, Chen N, Vassal G. Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer. Eur J Cancer. 2018 Sep;100:27-34. doi: 10.1016/j.ejca.2018.05.002. Epub 2018 Jun 21.
- pmid
- 29936064
- type
- BACKGROUND
- citation
- Amoroso L, Castel V, Bisogno G, Casanova M, Marquez-Vega C, Chisholm JC, Doz F, Moreno L, Ruggiero A, Gerber NU, Fagioli F, Hingorani P, Melcon SG, Slepetis R, Chen N, le Bruchec Y, Simcock M, Vassal G. Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network. Eur J Cancer. 2020 Aug;135:89-97. doi: 10.1016/j.ejca.2020.04.031. Epub 2020 Jun 15.
- pmid
- 32554315
- type
- DERIVED
- citation
- Hattinger CM, Patrizio MP, Magagnoli F, Luppi S, Serra M. An update on emerging drugs in osteosarcoma: towards tailored therapies? Expert Opin Emerg Drugs. 2019 Sep;24(3):153-171. doi: 10.1080/14728214.2019.1654455. Epub 2019 Aug 14.
- pmid
- 31401903
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-c4bd71a523c6809874fc
- requested nct id
- NCT01962103
- primary nct id
- NCT01962103
- source kind
- fda_spl_label
- source record id
- d1c7770f-7099-4ad3-84e2-20e638cb224e
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- payload sha256
- 59eac34c9431b4bde152f4b0e6311b05eb1ccea5309f2689f4c364217a9e9caa
- payload
- application numbers
- NDA021660
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-c4bd71a523c6809874fc
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT01962103
- occurrences
- context exact
- have not been established. Pharmacokinetics, safety, and antitumor activity of ABRAXANE were assessed in an open-label, dose escalation, dose expansion study (NCT01962103) in 96 pediatric patients aged 1.4 to < 17 years with recurrent or refractory pediatric solid tumors. The maximum tolerated dose (MTD) normalized for body surf
- end
- 235
- exact text
- NCT01962103
- start
- 224
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00600.json
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source json pointer
- /results/88/pediatric_use/0
- source kind
- fda_spl_label
- source record id
- d1c7770f-7099-4ad3-84e2-20e638cb224e
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 06b1f56ea1c1a9dd413933230f961a1fac8c820838dc34c8a7cfe005723dfe92
- spl effective time
- 20221031
- spl set id
- 24d10449-2936-4cd3-b7db-a7683db721e4
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-c95e07d33c418114c023
- requested nct id
- NCT01962103
- primary nct id
- NCT01962103
- source kind
- fda_spl_label
- source record id
- 5db1c7ab-35c2-4764-b1ae-33f44560883b
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- payload sha256
- e57c00f640702f6142baba63b966671d5b15db36386ccb90d29ab1e57cc18438
- payload
- application numbers
- NDA211875
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-c95e07d33c418114c023
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT01962103
- occurrences
- context exact
- stablished. Pharmacokinetics, safety, and antitumor activity of protein bound paclitaxel were assessed in an open-label, dose escalation, dose expansion study (NCT01962103) in 96 pediatric patients aged 1.4 to < 17 years with recurrent or refractory pediatric solid tumors. The maximum tolerated dose (MTD) normalized for body surf
- end
- 251
- exact text
- NCT01962103
- start
- 240
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00300.json
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- source json pointer
- /results/99/pediatric_use/0
- source kind
- fda_spl_label
- source record id
- 5db1c7ab-35c2-4764-b1ae-33f44560883b
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 891977417e740cb1d63a2fa3516cdd3c6bc621c09b996f6397c42b3f3bfb748f
- spl effective time
- 20230501
- spl set id
- f06d1bb3-83f1-4d84-8004-4c6681ad8a5a
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-d013a4724841d1e58fbf
- requested nct id
- NCT01962103
- primary nct id
- NCT01962103
- source kind
- fda_spl_label
- source record id
- d1c7770f-7099-4ad3-84e2-20e638cb224e
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- payload sha256
- aaf864d0a9fcf2ad867758f006e608f4a946d8b7005dcdc8d1d2f8e0344d80be
- payload
- application numbers
- NDA021660
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-d013a4724841d1e58fbf
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT01962103
- occurrences
- context exact
- have not been established. Pharmacokinetics, safety, and antitumor activity of ABRAXANE were assessed in an open-label, dose escalation, dose expansion study (NCT01962103) in 96 pediatric patients aged 1.4 to < 17 years with recurrent or refractory pediatric solid tumors. The maximum tolerated dose (MTD) normalized for body surf
- end
- 3698
- exact text
- NCT01962103
- start
- 3687
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00600.json
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source json pointer
- /results/88/use_in_specific_populations/0
- source kind
- fda_spl_label
- source record id
- d1c7770f-7099-4ad3-84e2-20e638cb224e
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- f77005e35ebbecb2257dbfb570dc8dc01e279ca65db6d6ec69e0a0922f5001b1
- spl effective time
- 20221031
- spl set id
- 24d10449-2936-4cd3-b7db-a7683db721e4
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-ea599b82b4359108084a
- requested nct id
- NCT01962103
- primary nct id
- NCT01962103
- source kind
- fda_spl_label
- source record id
- 5db1c7ab-35c2-4764-b1ae-33f44560883b
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- payload sha256
- 02a7cd85a196d04570aff61fdc6f5147f171d381543e83089bdb7ae95d4387a2
- payload
- application numbers
- NDA211875
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-ea599b82b4359108084a
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT01962103
- occurrences
- context exact
- stablished. Pharmacokinetics, safety, and antitumor activity of protein bound paclitaxel were assessed in an open-label, dose escalation, dose expansion study (NCT01962103) in 96 pediatric patients aged 1.4 to < 17 years with recurrent or refractory pediatric solid tumors. The maximum tolerated dose (MTD) normalized for body surf
- end
- 4308
- exact text
- NCT01962103
- start
- 4297
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00300.json
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- source json pointer
- /results/99/use_in_specific_populations/0
- source kind
- fda_spl_label
- source record id
- 5db1c7ab-35c2-4764-b1ae-33f44560883b
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 6fd690785c296db485b24ac31370d0b4f88638e50cae279a43c884b50a1bbf90
- spl effective time
- 20230501
- spl set id
- f06d1bb3-83f1-4d84-8004-4c6681ad8a5a
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-eb72ae2ae0d355cd6efd
- requested nct id
- NCT01962103
- primary nct id
- NCT01962103
- source kind
- fda_spl_label
- source record id
- 2fbc2699-cf99-497c-94b9-8a2c534c061f
- source file sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- payload sha256
- 51a79227483a7b6778ad9052dc5158c7b0a5ebf68c97d0a5104370fc4b15da0f
- payload
- application numbers
- NDA216338
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-eb72ae2ae0d355cd6efd
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT01962103
- occurrences
- context exact
- activity of Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound) were assessed in an open-label, dose escalation, dose expansion study (NCT01962103) in 96 pediatric patients aged 1.4 to < 17 years with recurrent or refractory pediatric solid tumors. The maximum tolerated dose (MTD) normalized for body surf
- end
- 303
- exact text
- NCT01962103
- start
- 292
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00100.json
- source file sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source json pointer
- /results/74/pediatric_use/0
- source kind
- fda_spl_label
- source record id
- 2fbc2699-cf99-497c-94b9-8a2c534c061f
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 2064d8ed600d8a951c2786007dbc1b126883b049c2022109dd1a499201ea77ea
- spl effective time
- 20231101
- spl set id
- 15dd51ed-29e8-468b-b6d1-21b1f84d6f2e
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-eca03413acb4a5918c28
- requested nct id
- NCT01962103
- primary nct id
- NCT01962103
- source kind
- fda_spl_label
- source record id
- 2fbc2699-cf99-497c-94b9-8a2c534c061f
- source file sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- payload sha256
- 7549b8384651f110120c3b134179db02a88ac6dd24395dca42bb25908da953fa
- payload
- application numbers
- NDA216338
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-eca03413acb4a5918c28
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT01962103
- occurrences
- context exact
- activity of Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound) were assessed in an open-label, dose escalation, dose expansion study (NCT01962103) in 96 pediatric patients aged 1.4 to < 17 years with recurrent or refractory pediatric solid tumors. The maximum tolerated dose (MTD) normalized for body surf
- end
- 4276
- exact text
- NCT01962103
- start
- 4265
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00100.json
- source file sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source json pointer
- /results/74/use_in_specific_populations/0
- source kind
- fda_spl_label
- source record id
- 2fbc2699-cf99-497c-94b9-8a2c534c061f
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 56714553c11a0d6d25e237ac48873b152eb0fa7a2a3a679d330c707b66f61400
- spl effective time
- 20231101
- spl set id
- 15dd51ed-29e8-468b-b6d1-21b1f84d6f2e
Preserved source evidence · Not medical advice